Cytokine/chemokine profiling by mesoscale U-plex assay further showed that, in the Moc2 EphB4 KO tumor-bearing DEREG mice, there was an increase in the secretory levels of IP-10/CXCL10, MIP-1α, RANTES, TNF-α, and MDC/CCL22 (Fig. 7i), all of which have been shown to play an integral role in DC recruitment to the tumor enhancing responsiveness towards DC-based immunotherapy agents, resulting in maximal control of tumor growth40–44. This evidence concerns the gene CCL5 and neoplasm.